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OBJECTIVE — While glucose tolerance abnormalities are common in cystic ﬁbrosis (CF),
impairedfastingglucose(IFG)hasscarcelybeenexplored.Nostudieshaveexaminedtherelation
between IFG and clinical status.
RESEARCH DESIGN AND METHODS — Data were retrieved from the University of
Minnesota CF database on oral glucose tolerance tests (OGTTs) performed in 1996–2005.
Subjects were identiﬁed as normal glucose tolerance (NGT), impaired glucose tolerance (IGT),
or CF–related diabetes without fasting hyperglycemia (CFRD FH). Patients with fasting hy-
perglycemiawereexcluded.ThepresenceofIFGwasassessedwithineachcategory.Inaseparate
case-control cohort study, subjects with IFG were matched to CF control subjects by age, sex,
and OGTT class to explore outcomes.
RESULTS — For the total population (n  310), the prevalence of IFG was 22%, and by
OGTT class was NGT 14%, IGT 31%, CFRD FH 53%. Within the cohort study, mortality was
signiﬁcantly reduced in IFG (two vs. nine deaths, odds ratio [OR]  0.2 [95% CI 0.04–0.9]).
IFG did not confer increased risk of progression to diabetes (OR 0.66 [0.29–1.48]). Lung
function was better in pediatric IFG subjects with IGT and not signiﬁcantly worse in adults with
IGToradultsandchildrenwithNGTandCFRDFH.BMIwasnotsigniﬁcantlydifferentinIFG
subjects versus control subjects.
CONCLUSIONS — Contrary to expectations in patients with CF, IFG appeared to be asso-
ciatedwithimprovedsurvivalandwasnotassociatedwithworsenutritionalorpulmonarystatus
or increased progression to fasting hyperglycemia.
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O
ral glucose tolerance test (OGTT)
categories were deﬁned decades
ago by the World Health Organiza-
tion (WHO). In 1997, the American Dia-
betes Association (ADA) lowered the
fasting glucose level used to deﬁne diabe-
tes from 140 mg/dl (7.8 mmol/l) to 126
mg/dl(7.0mmol/l)tobetterreﬂectriskof
microvascular complications. The ADA
also introduced the concept of impaired
fasting glucose (IFG) because fasting glu-
cose elevation in the range of 110–125
mg/dl (6.1–6.9 mmol/l) was shown to be
a risk factor for the development of dia-
betes. In 2003, the ADA further lowered
this prediabetes threshold to 100 mg/dl
(5.6), again based on the future risk of
developing diabetes. Using these newer
criteria, the prevalence of IFG in the gen-
eral population may be as high as 30%
among U.S. adults (1) and 11% among
adolescents (2).
Oral glucose tolerance abnormalities
are found in the majority of patients with
cystic ﬁbrosis (CF) (3), but IFG has been
infrequently reported (4,5). No studies
have reported current or future clinical
outcomes in CF patients with IFG. Be-
cause impaired glucose tolerance (IGT) is
associatedwithpulmonaryfunctiondete-
riorationinCF(6)andriskofprogression
to diabetes (7), we hypothesized that IFG
would also be associated with worse clin-
ical status and the development of diabe-
tes. Our aim was to determine the
prevalence of IFG in the University of
Minnesota (UM) CF population and the
consequences of that diagnosis over a pe-
riod of at least 3.5 years’ follow-up.
RESEARCH DESIGN AND
METHODS— CF patients at the UM
CF Center are routinely seen at quarterly
intervals,andtheirclinicalandlaboratory
data are recorded in the CF database. An-
nual OGTT screening starts at 6 years of
age for pancreatic-insufﬁcient patients
not already on insulin treatment for dia-
betes. Review of a prospectively collected
database was performed to determine the
prevalence of IFG. Clinical data were re-
trieved from patients who had an OGTT
performed between January 1, 1996, and
December 31, 2005, to identify individu-
alswhohadIFGasdeﬁnedbyfastingglu-
cose 100–125 mg/dl (5.6–6.9 mmol/l).
All patients and their parents gave in-
formed consent, permitting their records
tobereviewedforresearchpurposes.This
was approved by the institutional review
board.
Population prevalence study
Subjects who had at least one OGTT per-
formed during the study period were
identiﬁed as having normal glucose toler-
ance (NGT), IGT, cystic ﬁbrosis–related
diabetes without fasting hyperglycemia
(CFRD FH) or CFRD with fasting hy-
perglycemia (CFRD FH) by standard
deﬁnitions (Table 1). Additionally, the
presence of IFG was noted within each of
the ﬁrst three categories. As CF patients
may have ﬂuctuations in the OGTT cate-
gory from year to year, baseline for sub-
jects with IFG was considered the OGTT
within the study period when they ﬁrst
demonstrated fasting glucose elevation.
For all other subjects, baseline OGTT was
their ﬁrst OGTT in the study period.
Case-control cohort study
Following the initial population assess-
ment of IFG prevalence, a case-control
cohort study was performed. Subjects
with IFG were matched by age, sex, and
OGTT category to CF patients with nor-
mal fasting glucose (NFG) levels. Patients
were evaluated for subsequent progres-
siontoCFRDFH,changesinlungfunc-
tion and nutritional status, and death
during the study period. Lung function
wasdeterminedbychangeinforcedexpi-
ratory volume in 1 s (FEV1) and forced
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was determined by BMI.
Baseline characteristics
Subjects were determined to be pancre-
atic insufﬁcient based on their need for
enzyme replacement therapy. Subjects
were screened for cystic ﬁbrosis trans-
membrane regulator mutations. Only pa-
tients with diabetes with fasting
hyperglycemia, and thus none of the pa-
tients included in the current analysis,
were treated with insulin.
Clinical outcome measures
OGTTs occurred during yearly screening
visits when patients were determined to
be in a state of stable baseline health.
Studies were postponed for at least 1
month after acute illness. Fasting status
(8 h) was veriﬁed before testing. Glu-
cose 1.75 g/kg (maximum 75 g) was
orally administered. Blood was sampled
through an indwelling catheter for glu-
coseandinsulinlevelsattime0andevery
30 min for 2 h. Plasma insulin levels were
measured in the UM Fairview Laboratory
by radioimmunoassay using a double-
antibody method.
Fasting weight was measured on the
same calibrated clinic scale at each visit,
andheightwasmeasuredintriplicateona
wall-mounted stadiometer. BMI results
forchildrenandadolescents18yearsof
age were reported as BMI percentile. Be-
cause a portion of the children were 18
years of age by the end of the study, pedi-
atric BMI percentiles were reported for
baseline values only. Adult values were
reported at baseline and follow-up. Over-
all group values were reported for those
18 years of age only; therefore, data in-
cludes 96 individuals at baseline and 122
individuals at follow-up.
FEV1 and FVC were measured by
standardized American Thoracic Society
methods. For patients who died during
the study period, ﬁnal pulmonary func-
tion tests and weights included in the
analyses were obtained at least 60 days
before the time of death to exclude acute
changes.
Data analysis
The effect of IFG within each glucose tol-
erance category was estimated in the
paired case-control study using a mixed-
effect linear model with a random effect
foreachpairtoaccountforthecorrelation
between patients in a pair. Odds ratio
(OR) for death and progression to CFRD
FH were estimated from conditional lo-
gisticregressionstratiﬁedbypairs.
2was
used to compare IFG prevalence and the
percentage of children between groups.
All analyses were performed in SAS, ver-
sion 9.2 (SAS Institute, Cary NC).
In the analysis of the clinical out-
comes, similar patterns were found with
andwithoutinclusionofthepatientswho
died, except that the paradoxical im-
provement in FEV1 in CFRD FH be-
came no change when deceased patients
were excluded from baseline and fol-
low-up (data not shown); therefore, the
entire matched sample was used for sta-
tistical analyses.
RESULTS
Prevalence of IFG in the total study
population
Ofthe310subjectsinthetotalstudypop-
ulation, IFG was found in 22% (Table 1).
The prevalence of IFG increased with the
severity of the OGTT glucose category,
from 14% of those with NGT, 31% of
IGT, and 53% of CFRD FH (P 
0.0001). When only patients with fasting
glucose levels 110–125 mg/dl (6.1–6.9
mmol/l) were considered IFG (WHO cri-
teria), the overall prevalence of IFG was
19%andbyOGTTclasswasNGT12.5%,
IGT 25%, and CFRD FH 46%.
Subject characteristics at baseline,
cohort study
For the cohort study, subjects with IFG
and their matched NFG control subjects
showednodifferenceinsex,race,orbase-
line age (Table 2). Pancreatic insufﬁ-
ciency status was not signiﬁcantly
different (93% control subjects vs. 99%
IFG case subjects, P  0.73). CF muta-
tions were similar between case subjects
and control subjects with half of patients
homozygous and 40% heterozygous for
F508. The year of study entry was ear-
lier for IFG case subjects than for control
subjects but when looked at by OGTT
group, this was only signiﬁcant for CFRD
FH(NGT9months,P0.25;IGT
15 months, P  0.10; CFRD FH24
months, P  0.02). The frequency of
OGTT evaluation was similar between
groups(3.6vs.3.7perpatient,P0.75).
Table 3 shows the clinical character-
istics of subjects and control subjects by
glucosetolerancecategoryforthetotalco-
hort and broken down by pediatric and
adult age-groups. IFG subjects were
matchedforsexinallthreecategoriesand
were matched as closely as possible for
age to control subjects; however, adult
IFG subjects in the IGT group were on
average 2.4 years older than the control
subjects (P  0.03) (Table 3). The pro-
portion of children 18 years of age was
higher in NGT (38%) than in IGT (33%)
and CFRD FH (28%), but these differ-
ences were not signiﬁcant.
At baseline, IFG case subjects within
the IGT category had signiﬁcantly better
Table 1—Classiﬁcation of glucose tolerance abnormalities in CF
Fasting plasma glucose
mg/dl (mmol/l)
2-h OGTT glucose
mg/dl (mmol/l)
Number within
category (%)
NGT 100 (5.6) 140 (7.8) 175 (86)
NGT  IFG 100–125 (5.6–6.9) 140 (7.8) 29 (14)
IGT 100 (5.6) 140–199 (7.8–11.1) 50 (69)
IGT IFG 100–125 (5.6–6.9) 140–199 (7.8–11.1) 22 (31)
CFRD FH 100 (5.6) 200 (11.1) 16 (47)
CFRD FHIFG 100–125 (5.6–6.9) 200 (11.1) 18 (53)
CFRD FH 126 (7.0) 200 (11.1) NA
Because OGTT results can vary from year to year, patients are categorized based on the ﬁrst OGTT with IFG
during the test period, or for those who never developed IFG, the ﬁrst OGTT during the test period.
Table 2—Case-control cohort study: demo-
graphic summary for pairs matched on age
and sex
NFG IFG
Number (% male) 68 (50) 68 (50)
Baseline age, years 25  11 26  12
Race
White 65 (96) 66 (97)
Nonwhite 2 (3) 2 (3)
Unknown 1 (1) 0 (0)
Pancreatic insufﬁciency 63 (93) 67 (99)
Genotype
Homozygous F508 34 (50) 33 (49)
Heterozygous F508 27 (40) 29 (43)
Other 7 (10) 6 (9)
Values are mean  SD or n (%). There were no
statistical differences between groups.
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their control subjects with an 	20%
higher FEV1 and a 10% higher FVC (P 
0.005 and 0.033, respectively). This was
primarily related to better lung function
in pediatric patients with IGT who had
30%higherFEV1atbaseline(P0.008).
While adults with IFG had a 28% higher
FEV1 at baseline than their NFG control
subjects, it did not achieve statistical sig-
niﬁcance (P  0.081). Lung function for
both children and adults did not signiﬁ-
cantly differ between subjects with IFG
and their NFG control subjects in the
NGT or CFRD FH categories.
Clinical status at follow-up
Overall there was a slightly longer dura-
tionoffollow-upfortheIFGsubjects(7.6
vs. 6.2 years). Within glucose tolerance
categories, this difference was signiﬁcant
onlyintheCFRDFHgroup(P0.003)
where it was related to the death rate of
ﬁve deaths in subjects with NFG versus
one death in an IFG subject.
Across all three glucose tolerance cat-
egories, the number of subjects who died
amongtheIFGcasesubjectswaslessthan
or equal to the number of deaths in the
control subjects for that group. Only two
subjects with IFG died during the fol-
low-upperiod,comparedwithnineinthe
NFG control group. The overall odds of
death was eight times higher for control
subjects than IFG case subjects (95% CI
1.001–64, P  0.0499, based on nine in-
formative pairs where paired participants
had different outcomes).
At follow-up, analysis of lung func-
tionshowedthatwithintheIGTcategory,
FEV1 continued to be about 20% higher
andFVCabout15%higherinIFGthanin
control subjects with IGT and NFG (P 
0.008 and 0.023, respectively). When
children and adults with IGT were evalu-
ated separately, the difference in pulmo-
nary function was only signiﬁcant for
children. Mean follow-up FEV1 and FVC
in the IFG groups were lower in both the
NGT and CFRD FH categories. These
differences did not reach signiﬁcance.
Thus, IFG was not associated with differ-
ent pulmonary outcomes in the NGT and
CFRD FH categories, and it was associ-
ated with improved pulmonary status in
the IGT category, especially in children.
Progression to CFRD with fasting
hyperglycemia
In the IFG group, 57% of subjects pro-
gressed to CFRD FH compared with
50%ofthecontrolcasesubjects.Thiswas
consistent across NGT, IGT, and CFRD
Table 3—Case-control cohort study: clinical characteristics of all patients with IFG and their matched NFG CF control subjects
NGT NGT/IFG IGT IGT/IFG CFRD FH CFRD FH/IFG
Total cohort
Number (% male) 29 (48) 29 (48) 21 (48) 21 (48) 18 (56) 18 (56)
Baseline age (years) 26.3  2 26.6  2 23.2  3 *25.7  3 24.8  3 26.2  3
Baseline fasting insulin 6.6  1 9.5  1 6.0  1 9.5  1 8.4  2 4.7  2
Follow-up duration (years) 6.5  0.5 7.3  0.5 6.3  0.6 7.4  0.6 5.6  0.7 *8.2  0.7
Deaths, number (%) 3 (10) 0 1 (5) 1 (5) 5 (28) 1 (6)
Progression to CFRD FH 7 (24) 11 (38) 10 (48) 10 (48) 17 (94) 18 (100)
Baseline % predicted FEV1 85  57 6  56 6  6 *85  67 0  67 5  6
Follow-up† % pred FEV1 80  57 0  56 0  5 *79  67 8  77 7  6
Baseline % predicted FVC 92  48 9  48 4  5 *95  58 4  59 0  5
Follow-up† % predicted FVC 88  48 5  47 5  5 *90  59 5  69 2  5
Children 18 years
Number (% male) 11 (45) 11 (45) 7 (29) 7 (29) 5 (20) 5 (20)
Baseline age (years) 12  11 2  11 4  21 4  21 6  21 6  2
Baseline fasting insulin 5.5  21 0  2 5.6  2 7.4  21 0  3 5.7  3
Follow-up duration (years) 7.2  1 6.5  1 5.9  1 5.5  1 6.7  1 8.5  1
Deaths, number (%) 1 (9) 0 0 0 1 (20) 0
Progression to CFRD FH 3 (27) 4 (36) 1(14) 0 5 (100) 5 (100)
Baseline BMI percentile 53  73 9  73 4  84 2  86 2  10 49  10
Baseline % predicted FEV1 97  79 8  78 3  9 *108  99 2  10 82  10
Follow-up† % predicted FEV1 85  78 4  76 6  8 *107  89 5  11 81  10
Baseline % predicted FVC 101  7 104  79 7  9 112  9 100  10 94  10
Follow-up† % predicted FVC 93  69 5  67 9  7 *115  7 106  99 6  8
Adults
Number (% male) 18 (56) 18 (56) 14 (64) 14 (64) 13 (54) 13 (54)
Baseline age (years) 35  23 6  22 8  2 *31  22 8  23 0  2
Baseline fasting insulin 7  29  26  21 1  28  24  2
Follow-up duration (years) 6.5  0.7 7.4  0.7 6.5  0.8 8.3  0.8 5.2  0.7 *8.1  0.8
Deaths, number (%) 2 (11) 0 1 (7) 1 (7) 4 (31) 1 (8)
Progression to CFRD FH 4 (22) 7 (39) 9 (64) 10 (71) 12 (92) 13 (100)
Baseline BMI (kg/m
2) 25.2  1 24.1  1 21.9  1 25.4  1 21.5  1 23.3  1
Follow-up BMI (kg/m
2) 25.3  1 23.6  1 22.5  1 25.1  1 21.5  1 23.9  1
Baseline % predicted FEV1 77  56 2  55 7  67 3  66 1  67 3  6
Follow-up† % predicted FEV1 76  66 1  65 7  66 5  67 0  87 6  7
Baseline % predicted FVC 86  48 0  47 7  58 6  57 8  58 9  5
Follow-up† % predicted FVC 85  57 8  57 3  57 6  69 0  79 1  6
Values are n (%) or mean  SE. *IFG signiﬁcantly different from control subject within category (P  0.05). †Follow-up % predicted FEV1 and FVC measured 60
days before death.
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gressing to CFRD FH was not signiﬁ-
cantly higher in IFG (OR 1.6 [95% CI
0.7–3.6], P  0.301, based on 23 infor-
mative pairs where paired participants
had different progression outcomes).
CONCLUSIONS — Fewreportshave
described IFG in CF. A German review of
1,128 OGTTs performed on CF patients
10–64 years of age found 32% with IFG,
but the data were not separated by OGTT
category, and many subjects had diabetes
(4). In an U.S. report of 73 children and
adolescents with CF, 18% with NGT and
33% with IGT had IFG (5). In the present
study of 310 children and adults, IFG was
found in 14% of those with NGT, 31% of
those with IGT, and 53% of those with
CFRD FH, with an overall prevalence of
22%.
Diabetes is associated with increased
morbidity and mortality in CF. Nutri-
tional status and pulmonary function be-
gin to decline several years before the
diagnosisofCFRD,inthepre-diabeticpe-
riod (8,9), where clinical deterioration
correlateswiththedegreeofinsulininsuf-
ﬁciency (10). Insulin insufﬁciency allows
acatabolicstate,negativelyimpactingnu-
trition and lung function (9,11). We hy-
pothesized that IFG, as part of the
spectrum of glucose tolerance abnormal-
ities in CF, would be associated with
worse outcomes. This was not the case.
Mortality was signiﬁcantly reduced in pa-
tients with IFG, and lung function was
betterinpediatricpatientswithIFGinthe
IGT group and not signiﬁcantly worse in
adults with IFG and IGT or in children
and adults with IFG in the NGT and
CFRD FH groups.
Anexplanationfortheunexpectedas-
sociation of IFG with improved or no
worseclinicaloutcomesmaylieintheeti-
ology of IFG. In the general population,
epidemiologic studies suggest that IFG
and IGT are two distinct categories with
only partial overlap (12–15). Both IFG
and IGT identify individuals at risk for
future diabetes, involve impairment of
early (ﬁrst-phase) insulin secretion, and
are associated with insulin resistance
(16). The site of insulin resistance differs,
however.InIFG,itoccursprimarilyinthe
liver, which results in excessive hepatic
glucoseproduction(HGP)andfastinghy-
perglycemia despite normal fasting insu-
linlevels.Fastinghyperglycemiamayalso
be related to impaired glucose–mediated
glucose uptake (glucose uptake not re-
lated to insulin, which predominates in
the fasting state) (14). Because peripheral
muscle insulin sensitivity and late (sec-
ond-phase) insulin secretion are normal
in patients with IFG, glucose levels normal-
ize after a glucose load. In contrast, insulin
resistance in IGT occurs primarily in skele-
tal muscle; this, combined with defective
second–phase insulin secretion, results in
postload hyperglycemia (12,15).
In CF, euglycemic clamp studies
demonstrate normal peripheral insulin
sensitivity in nondiabetic CF patients and
only mild peripheral insulin resistance in
those with diabetes (17). For reasons that
areunclear,incontrasttoperipheralskel-
etal muscle, hepatic insulin resistance
withincreasedHGPisfoundeveninnon-
diabetic CF patients with completely
NFG levels (17–20). Glucose-mediated
glucose uptake is normal (17). Because
elevated HGP correlates with resting en-
ergy expenditure (18), we and others
(17,18) have hypothesized that NFG lev-
els are seen in the face of increased HGP
because of an adaptive physiologic bal-
ancebetweenhighglucoseutilizationand
elevated glucose production. The current
study supports this hypothesis since
healthier, better nourished CF patients
would be expected to have lower resting
energy needs in the fasting state, thus less
ability to metabolize extra glucose pro-
duced by the liver and leading to IFG
(Fig. 1).
The relation between IFG and better
pulmonarystatuswasonlyseeninthepa-
tientswithIGT.Thisrelationwasnotseen
in the NGT patients, who were healthier
as a group. In the CFRD FH group, the
relation between IFG and clinical status
may have been obscured by the greater
degreeofinﬂammationandperipheralin-
sulin resistance that characterizes CF pa-
tients with diabetes. Nonetheless, the
greatest impact on survival was seen in
theCFRDFHgroup(thestudygroupat
the highest risk for imminent death).
Within the IGT group, children with IFG
and their control subjects were the same
age, while adults with IFG were 2.4 years
older than their control subjects. Al-
though the difference in lung function
compared with control subjects was only
signiﬁcant in children, the observation
that adults with IGT and IFG were no
worse than their younger control subjects
may be clinically important since lung
function declines with age in CF.
Unlike the general population where
IFG is a pre-diabetic state, the current
study demonstrates that IFG does not ap-
pear to be an independent risk factor for
the progression to diabetes in CF, although
there is a nonstatistically signiﬁcant sugges-
tion that it may confer increased risk in
those with NGT. The extraordinarily high
rate of progressive glucose tolerance abnor-
malitiesleadingtodiabetesinCFmayover-
whelm any relation between IFG and the
future risk of diabetes.
While IGT is well known to be a risk
factor for cardiovascular disease in the
general population, it was initially re-
portedthatnosuchassociationexistedfor
IFG (21). In the Framingham Heart
Study, however, IFG was found to be as-
sociated with increased risk of coronary
heartdiseaseinwomenbutnotmen(22).
This is interesting given that a sex differ-
ence in mortality has also been reported
inCFRD.Theaddeddiagnosisofdiabetes
hasbeenassociatedwithreducedsurvival
in women but not men with CF, albeit
from inﬂammatory lung rather than in-
ﬂammatory cardiovascular disease
(23,24). Recently gender differences in
mortality have disappeared at UM, per-
haps because of more aggressive diabe-
Figure 1—Model for fasting blood glucose and IFG in CF. A: In the normal population, fasting
HGP is balanced by total body glucose utilization (GU). B: Inﬂammation, undernutrition, and
perhaps the CF gene defect increase GU in CF patients. HGP is elevated for reasons that are not
understood very well, but fasting glucose levels are normal when HGP and GU are in balance. C:
In healthier CF patients, HGP is similarly elevated but GU is reduced, leading to IFG.
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sex differences were apparent in the
current study, but the sample size may
have been too small for meaningful
conclusions.
Themajorlimitationofthisstudywas
therelativelysmallnumberofsubjects.In
addition,thelengthoffollow-upwasonly
about5.5years.Greatervariabilityinlung
function was seen in adults with NGT,
and it cannot be ruled out that the sample
was too small to detect clinically signiﬁ-
cant differences. Longitudinal assessment
of this cohort will be important to deter-
mine whether current ﬁndings persist.
IFG subjects and control subjects were
matched by age at OGTT rather than year
ofentrysothattheIFGcasesubjectswere
enrolled on average 16 months earlier
thantheNFGcontrolsubjects(signiﬁcant
only in the CFRD FH group). At UM
and elsewhere, the CF population has
shown a trend toward improvement in
outcomes over the years, implying later
enrollment would confer improved clini-
cal outcome. Thus, the earlier enrollment
would be expected to result in a bias to-
wardworseclinicaloutcomes,ratherthan
the better results that were found in the
IFG group.
In summary, IFG is relatively com-
mon in the CF population. It does not
signifyincreasedriskofprogressiontodi-
abetes. In our study, it is associated with
improved survival, and it appears to be
associated with improved pulmonary sta-
tus in pediatric patients with IGT. Larger
studies are needed to conﬁrm these
observations.
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